These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. DJ-1 in endometrial cancer: a possible biomarker to improve differential diagnosis between subtypes. Morelli M; Scumaci D; Di Cello A; Venturella R; Donato G; Faniello MC; Quaresima B; Cuda G; Zullo F; Costanzo F Int J Gynecol Cancer; 2014 May; 24(4):649-58. PubMed ID: 24614826 [TBL] [Abstract][Full Text] [Related]
6. MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium. Shaco-Levy R; Sharabi S; Piura B; Sion-Vardy N Acta Obstet Gynecol Scand; 2008; 87(8):868-74. PubMed ID: 18607832 [TBL] [Abstract][Full Text] [Related]
7. The expression pattern of CD10 and CD31 identifies fine fibrovascular stroma of grade 1-endometrial endometrioid carcinomas in cytology. Norimatsu Y; Nishikawa T; Suzuki H; Hosokawa S; Yano H; Maeda Y; Kurokawa T; Shinagawa A; Kobayashi TK; Fulciniti F Cytopathology; 2022 May; 33(3):362-373. PubMed ID: 34689374 [TBL] [Abstract][Full Text] [Related]
8. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas. Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803 [TBL] [Abstract][Full Text] [Related]
9. Morphological Differences between Liquid-Based Cytology and Conventional Preparation in Endometrial Endometrioid Carcinoma Grade 1 and Grade 3, and the Differentiation of Grades in Each Method. Odashima H; Yoshioka H; Ota K; Goto Y; Noro M; Horie K; Watanabe J Acta Cytol; 2021; 65(3):227-234. PubMed ID: 33652432 [TBL] [Abstract][Full Text] [Related]
10. Cytological nuclear atypia classification can predict prognosis in patients with endometrial cancer. Yamaguchi T; Kawahara A; Hattori S; Taira T; Abe H; Sanada S; Akiba J; Nishio S; Ushijima K; Kamura T; Kage M Cytopathology; 2015 Jun; 26(3):157-66. PubMed ID: 24827996 [TBL] [Abstract][Full Text] [Related]
11. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675 [TBL] [Abstract][Full Text] [Related]
13. Expression of immunoreactivity of nuclear findings by p53 and cyclin a in endometrial cytology: Comparison with endometrial glandular and stromal breakdown and endometrioid adenocarcinoma grade 1. Norimatsu Y; Ohsaki H; Yanoh K; Kawanishi N; Kobayashi TK Diagn Cytopathol; 2013 Apr; 41(4):303-7. PubMed ID: 21954041 [TBL] [Abstract][Full Text] [Related]
14. IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas. Zhang L; Liu Y; Hao S; Woda BA; Lu D Am J Surg Pathol; 2011 Jun; 35(6):868-72. PubMed ID: 21566514 [TBL] [Abstract][Full Text] [Related]
15. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334 [TBL] [Abstract][Full Text] [Related]
16. Undifferentiated Carcinoma of the Endometrium: An Expanded Immunohistochemical Analysis Including PAX-8 and Basal-Like Carcinoma Surrogate Markers. Ramalingam P; Masand RP; Euscher ED; Malpica A Int J Gynecol Pathol; 2016 Sep; 35(5):410-8. PubMed ID: 26598976 [TBL] [Abstract][Full Text] [Related]
17. Cervical cytology in serous and endometrioid endometrial cancer. Roelofsen T; Geels YP; Pijnenborg JM; van Ham MA; Zomer SF; van Tilburg JM; Snijders MP; Siebers AG; Bulten J; Massuger LF Int J Gynecol Pathol; 2013 Jul; 32(4):390-8. PubMed ID: 23722512 [TBL] [Abstract][Full Text] [Related]